Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BMS Gets First Immunotherapy Approval In Neoadjuvant Lung Cancer, Quickly

Mar 07 2022

• By Joseph Haas

Checkmate — Data from the CheckMate-816 study earns Bristol another indication for Opdivo • Source: Alamy

Related Content

Earlier-Stage Approvals For Tecentriq, Keytruda, Verzenio Underscore Broader Oncology Trends

Oct 15 2021

Keeping Track: US FDA Approves Carvykti, Vonjo, But Turns Down Lenacapavir, Filsuvez And GC1507

Mar 05 2022

AACR Round-Up: BMS, Lilly, iTeos, Affimed, Treovir, Revolution And Cardiff

Apr 13 2021

New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

Sep 21 2021

BMS Prepares To Move Opdivo Into Neoadjuvant Lung Cancer

Nov 08 2021

Bristol Claims A First With Opdivo In Neoadjuvant NSCLC

Oct 07 2020

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Roche Holding AG

Genentech, Inc.

Additional Topics

Approvals ImmunoOncology Business Strategies Clinical Trials Commercial Research & Development BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window